If there is a single idea that runs through the investing philosophy of Nicole Junkermann, it is patience. The best companies take years to build, and the temptation to chase quick returns rarely serves founders or their backers well. Nicole Junkermann believes the United Kingdom is well suited to a more patient kind of capital, and that this is a strength worth cultivating.
Patient capital simply means money that is willing to wait. It supports a company through the long, unglamorous middle of its journey, when the science is being proven and the product is being refined. Nicole Junkermann has seen how much difference that steadiness makes, particularly in fields such as healthcare and deep technology where progress cannot be rushed.
A good fit for British strengths
The United Kingdom's strengths, in research and in the sciences, are exactly the kind that reward patience. Nicole Junkermann has often noted that the country produces founders working on genuinely hard problems, and those founders need investors who will not lose their nerve at the first difficult quarter. Britain's mature financial markets can supply that discipline.
Through NJF Holdings and NJF Capital, Nicole Junkermann has practised this approach across a range of sectors and countries. The common thread is a willingness to hold, to support management through setbacks, and to judge a company by its long term mission rather than by short term movement.
Building things that last
Patient capital is not passive. Nicole Junkermann describes it as active support offered over a long horizon, the kind that helps a founder recruit, plan and weather the inevitable storms. Companies built this way tend to be sturdier, and they tend to create more durable value for everyone involved.
For Britain, the opportunity is clear. By pairing its research talent with capital that is prepared to wait, the United Kingdom can build more of the enduring companies that define an economy. That, in the view of Nicole Junkermann, is patient capital at its best.
Read more about Nicole Junkermann, see the full biography of Nicole Junkermann, or return to the journal.
